Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Zosano Pharma Corp (ZSAN) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/13/2022 8-K Quarterly results
03/17/2022 8-K Quarterly results
Docs: "Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results"
11/10/2021 8-K Quarterly results
Docs: "Zosano Pharma Reports Third Quarter 2021 Financial Results"
03/11/2021 8-K Quarterly results
11/13/2020 8-K Quarterly results
Docs: "Zosano Pharma Reports Third Quarter 2020 Financial Results"
08/06/2020 8-K Quarterly results
05/14/2020 8-K Quarterly results
03/13/2020 8-K Quarterly results
11/14/2019 8-K Quarterly results
05/14/2019 8-K Quarterly results
Docs: "Zosano Pharma Reports First Quarter 2019 Financial Results • Multiple catalysts, including Qtrypta TM NDA submission, anticipated in 2019 • Company bolstered balance sheet to advance proprietary programs and expand applicability of ADAM microneedle technology • Conference call scheduled for 1:30 pm PT today"
03/14/2019 8-K Quarterly results
Docs: "Zosano Pharma Reports Fourth Quarter and Fiscal Year 2018 Financial Results"
11/14/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Zosano Pharma Reports Third Quarter 2018 Financial Results and Operational Update"
08/09/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Zosano Pharma Reports Second Quarter 2018 Financial Results and Operational Update"
03/12/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 of The Securities Exchange Act of 1934 Date of report : March 12, 2018 ZOSANO PHARMA CORPORATION Delaware 001-36570 45-4488360 34790 Ardentech Court Fremont, CA 94555 745-1200 Registrant's telephone number, including area code Not applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commen...",
"Zosano Pharma Reports Fourth Quarter and Fiscal Year 2017 Financial Results and Operational Update"
11/09/2017 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 of The Securities Exchange Act of 1934 Date of report : November 9, 2017 ZOSANO PHARMA CORPORATION Delaware 001-36570 45-4488360 34790 Ardentech Court Fremont, CA 94555 745-1200 Registrant's telephone number, including area code Not applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-comm...",
"Zosano Pharma Reports Third Quarter 2017 Financial Results and Operational Update"
08/10/2017 8-K Quarterly results
Docs: "Zosano Pharma Reports Second Quarter 2017 Financial Results and Operational Update"
05/09/2017 8-K Form 8-K - Current report
03/01/2017 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
08/10/2016 8-K Quarterly results
Docs: "Zosano Pharma Reports Second Quarter 2016 Financial Results FREMONT, CA, August 10, 2016 - Zosano Pharma Corporation , an emerging CNS company focused on providing rapid symptom relief to patients using the Company's proprietary intracutaneous delivery system, today announced financial results for the second quarter ended June 30, 2016. “With the recent announcement of the first subject treated in our M207 pivotal efficacy trial for acute migraine, we remain on track to report data in Q1 2017,” said Dr. Konstantinos Alataris, Zosano's President and Chief Executive Officer. “I look forward to providing additional updates as the trial progresses.” As of August 8, 2016, 196 subjects were enrolled in the trial, 157 of whom were in the run-in phase, 29 subjects were randomized, and 13 of those ..."
05/12/2016 8-K Form 8-K - Current report
03/29/2016 8-K Form 8-K - Current report
11/09/2015 8-K Quarterly results
Docs: "ZOSANO PHARMA REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS"
08/12/2015 8-K Quarterly results
Docs: "Zosano Pharma Reports Second Quarter 2015 Financial Results"
05/11/2015 8-K Quarterly results
Docs: "Zosano Pharma Reports First Quarter 2015 Financial Results"
03/25/2015 8-K Quarterly results
Docs: "Zosano Pharma Reports 2014 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy